| Literature DB >> 34183306 |
Xanthe A M H van Dierendonck1, Kyra E de Goede1, Jan Van den Bossche2.
Abstract
Isocitrate dehydrogenase (IDH) mutations produce high levels of the 'oncometabolite' R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain. A recent study in Nature Cancer by Friedrich et al. describes how IDH-mutant-derived R-2-HG elicits an immunosuppressive phenotype in glioma-associated macrophages. As such, the authors uncovered a new vulnerability that can be exploited for therapy.Entities:
Keywords: R-2-hydroxyglutarate (R-2-HG); immunometabolism; immunosuppression; immunotherapy; isocitrate dehydrogenase (IDH)-mutant gliomas; tumor-associated macrophages
Mesh：
Substances：
Year: 2021 PMID： 34183306 DOI： 10.1016/j.trecan.2021.06.003
Source DB: PubMed Journal: Trends Cancer ISSN： 2405-8025